Warning Letter — Eugia Pharma Specialities Limited
The FDA issued a Warning Letter to Eugia Pharma Specialities Limited on August 13, 2026, following an inspection by the Center for Drug Evaluation and Research (CDER). The letter identifies regulatory violations at the firm's manufacturing facility.
This affects Eugia Pharma Specialities Limited, its supply chain partners, and regulatory/quality personnel responsible for overseeing sterile or finished dosage drug manufacturing at this facility.
A Warning Letter indicates that the FDA considers the facility's responses to previous inspectional observations insufficient to address underlying cGMP deviations. This may result in the withholding of new product approvals or import alerts if the cited deficiencies are not remediated to the agency's satisfaction, potentially disrupting product supply.
Quality and compliance teams should prepare for potential site-specific shipment impacts and conduct a rigorous internal audit of manufacturing records and aseptic controls to ensure alignment with current Good Manufacturing Practice (cGMP) standards. Verification of all outstanding CAPAs related to sterile production is advised.
FDA Warning Letter issued to: Eugia Pharma Specialities Limited. 08/13/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-730469-08132026
Open in openFDA / FDA.gov